Access to subsidized ACT and malaria treatment - Evidence from the first year of the AMFm program in six districts in Uganda

Health Policy and Planning

Volumn 29, Issue 4, 2014, Pages 517-527

  Fink, Günther ^a   Dickens, William T ^b   Jordan, Matthew ^c   Cohen, Jessica L ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c BROOKINGS INSTITUTION   (United States)

Author keywords

ACT; AMFm; Malaria; Subsidies

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE;

ADULT; CHILD; COMBINATION DRUG THERAPY; DRUG COST; ECONOMICS; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HUMAN; MALARIA; MALE; ORGANIZATION AND MANAGEMENT; UGANDA;

ADULT; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; ARTEMISININS; CHILD; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; FINANCING, GOVERNMENT; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALARIA; MALE; PRIVATE SECTOR; UGANDA;

EID: 84904280931     PISSN: 02681080     EISSN: 14602237     Source Type: Journal    
DOI: 10.1093/heapol/czt041     Document Type: Review

References (36)

1. Adeyi O, Atun R. 2010. Universal access to malaria medicines: innovation in financing and delivery. The Lancet 376: 3.
2. Bhattarai A, Ali AS, Kachur SP et al. 2007. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Medicine 4: e309.
3. Cohen J, Dupas P, Schaner S. 2012a. Price subsidies, diagnostic tests and targeting of malaria treatment: evidence from a randomized controlled trial. NBER Working Paper. 17943.
4. Cohen J, Fink G, Berg K et al. 2012b. Feasibility of distributing rapid diagnostic tests for malaria in the retail sector: evidence from an implementation study in Uganda. PLoS ONE 7: e48296.
5. Filmer D, Pritchett LH. 2001. Estimating wealth effects without expenditure data - or tears: an application to educational enrollments in states of India. Demography 38: 115-32.
6. Independent Evaluation Team. 2012. Independent Evaluation of the Affordable Medicines Facility - malaria (AMFm) Phase 1. ICF, Calverton, MD and London, UK.
7. Kamal-Yanni M. 2010. Affordable medicines facility for malaria: reasonable or rash? The Lancet 375: 121.
8. Kangwana B, Njogu J, Wasunna B et al. 2009. Malaria drug shortages in Kenya: a major failure to provide access to effective treatment. The American Journal of Tropical Medicine and Hygiene 80: 737-8.
9. Kangwana BP, Kedenge SV, Noor AM et al. 2011. The impact of retailsector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial. PLoS Medicine 8: e1000437.
10. Laxminarayan R, Gelband H. 2009. A global subsidy: key to affordable drugs for malaria? Health Affairs 28: 949-61.
11. Littrell M, Gatakaa H, Evance I et al. 2011. Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries. Malaria Journal 10: 327.
12. Marriott A, Kamal-Yanni M. 2012. Malaria, aid, and shopkeepers: saving lives or playing with fire? In: Global Health Check. Online at: http://www.globalhealthcheck.org/?p=837.
13. Maxmen A. 2012. Malaria subsidy pilot soars, but some see turbulence ahead. Nature Medicine 18: 634-5.
14. Mbonye AK, Bygbjerg IC, Magnussen P. 2008. Prevention and treatment practices and implications for malaria control in Mukono District Uganda. Journal of Biosocial Science 40: 283-96.
15. National Malaria Control Program. 2010. Uganda National Malaria Control Policy. Ministry of Health.
16. Nuwaha F. 2002. People's perception of malaria in Mbarara, Uganda. Tropical Medicine and International Health 7: 462-70.
17. O'Connell K, Gatakaa H, Poyer S et al. 2011. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malariaendemic countries. Malaria Journal 10: 1-14.
18. Otten M, Aregawi M, Were W et al. 2009. Initial evidence of reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scaleup of malaria prevention and treatment. Malaria Journal 8: 1-8.
19. Patouillard E, Hanson KG, Goodman CA. 2010. Retail sector distribution chains for malaria treatment in the developing world: a review of the literature. Malaria Journal 9: 50.
20. Sabot O, Yeung S, Pagnoni F et al. 2009a. Distribution of artemisininbased combination therapies through private-sector channels: lessons from four country case studies. Resources for the Future Discussion Paper 08-43.
21. Sabot OJ, Mwita A, Cohen JM et al. 2009b. Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. PLoS ONE 4: e6857.
22. StataCorp. 2009. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP.
23. Talisuna A, Grewal P, Rwakimari JB et al. 2009. Cost is killing patients: subsidising effective antimalarials. The Lancet 374: 1224-6.
24. The PLoS Medicine Editors. 2009. Time for a "Third Wave" of Malaria Activism to Tackle the Drug Stock-out Crisis. PLoS Med 6: 1-3.
25. Uganda Bureau of Statistics. 2002. 2002 Uganda Population and Housing Census. Kampala: Uganda Bureau of Statistics.
26. Uganda Bureau of Statistics. 2010. Uganda Malaria Indicator Survey 2009-2010. Calverton. Maryland, USA: ICF Macro.
27. Uganda Bureau of Statistics (UBOS) and ICF International Inc. 2012. Uganda Demographic and Health Survey 2011. Kampala, Uganda: UBOS and ICF International Inc.
28. WHO. 2003. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: WHO.
29. WHO. 2009. World Malaria Report 2008. Geneva: WHO.
30. WHO. 2010. Guidelines for the Treatment of Malaria, 2nd edn. Geneva: World Health Organization.
31. WHO. 2011. World Malaria Report 2011. Geneva: World Health Organization Global Malaria Programme.
32. WHO/UNICEF. 2005. World Malaria Report 2005. Geneva: World Health Organization.
33. World Health Organization. 2009. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: WHO.
34. Zambia Ministry of Health. 2012. Health Management Information System (HMIS). Lusaka: Health Mo.
35. Zurovac D, Ndhlovu M, Sipilanyambe N et al. 2007. Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malaria Journal 6: 1-9.
36. Zurovac D, Tibenderana J, Nankabirwa J et al. 2008. Malaria casemanagement under artemether-lumefantrine treatment policy in Uganda. Malaria Journal 7: 1-10.